Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII.

doi:10.1038/sj.bjc.6602793

Back to search

Article

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII.

British journal of cancer - 17 Oct 2005

Pedersen M W, Pedersen N, Ottesen L H, Poulsen H S

Abstract excerpt

Epidermal growth factor receptor (EGFR) is frequently amplified and/or mutated in a number of human tumours and abnormal signalling from this receptor is believed to contribute to the malignant phenotype seen in these tumours. Gefitinib is a small molecule inhibitor that specifically binds and in...

Topics

Cell Adhesion
Cell Proliferation
ErbB Receptors
Gefitinib
Gene Expression Regulation, Neoplastic
Humans
Phenotype
Phosphorylation
Protein Kinase Inhibitors
Quinazolines
Signal Transduction
Tumor Cells, Cultured

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.